magnesium-orotate and Connective-Tissue-Diseases

magnesium-orotate has been researched along with Connective-Tissue-Diseases* in 3 studies

Trials

2 trial(s) available for magnesium-orotate and Connective-Tissue-Diseases

Article	Year
[Magnesium orotate in treatment of chronic hypertension in pregnant women]. Kardiologiia, 2013, Volume: 53, Issue:9 We examined 150 pregnant women with essential hypertension (EHT), EHT and connective tissue dysplasia (CTD), and healthy. Presence of CTD aggravated clinical picture of EHT and was associated with pronounced cardialgic, neurological, asthenic, vertebrogenic, visceral, and other syndromes. The use of antihypertensive, metabolic (magnesium orotate) drugs, sedative and uroseptic phytotherapy, application of other nondrug measures in conditions of multidisciplinary dynamic support of the gestational period facilitated regress of clinical symptoms of EHT and EHT+CTD, favorable course of pregnancy and successful delivery. Topics: Adult; Antihypertensive Agents; Blood Pressure; Connective Tissue Diseases; Dietary Supplements; Drug Monitoring; Drug Therapy, Combination; Echocardiography; Female; Humans; Hypertension; Orotic Acid; Perinatal Mortality; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Severity of Illness Index; Siberia; Treatment Outcome	2013
[Adrenoreactivity in patients with arrhythmic syndrome associated with connective tissue dysplasia at the background of intake of the magnezium orotate]. Kardiologiia, 2011, Volume: 51, Issue:3 Elevated level of -adrenoreception of membranes is observed in patients with disturbances of heart rhythm at the background of connective tissue dysplasia. It is not related to characteristics of the arrhythmic syndrome. At the background of 4-months intake of preparation magnezium orotate significant decrease of degree of desensitization of of erythrocytes has been noted. Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Catecholamines; Connective Tissue Diseases; Erythrocyte Membrane; Female; Humans; Male; Orotic Acid; Receptors, Adrenergic, beta; Sympathetic Nervous System; Treatment Outcome	2011

Article

Year

[Magnesium orotate in treatment of chronic hypertension in pregnant women].

Kardiologiia, 2013, Volume: 53, Issue:9

We examined 150 pregnant women with essential hypertension (EHT), EHT and connective tissue dysplasia (CTD), and healthy. Presence of CTD aggravated clinical picture of EHT and was associated with pronounced cardialgic, neurological, asthenic, vertebrogenic, visceral, and other syndromes. The use of antihypertensive, metabolic (magnesium orotate) drugs, sedative and uroseptic phytotherapy, application of other nondrug measures in conditions of multidisciplinary dynamic support of the gestational period facilitated regress of clinical symptoms of EHT and EHT+CTD, favorable course of pregnancy and successful delivery.

Topics: Adult; Antihypertensive Agents; Blood Pressure; Connective Tissue Diseases; Dietary Supplements; Drug Monitoring; Drug Therapy, Combination; Echocardiography; Female; Humans; Hypertension; Orotic Acid; Perinatal Mortality; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Severity of Illness Index; Siberia; Treatment Outcome

2013

[Adrenoreactivity in patients with arrhythmic syndrome associated with connective tissue dysplasia at the background of intake of the magnezium orotate].

Kardiologiia, 2011, Volume: 51, Issue:3

Elevated level of -adrenoreception of membranes is observed in patients with disturbances of heart rhythm at the background of connective tissue dysplasia. It is not related to characteristics of the arrhythmic syndrome. At the background of 4-months intake of preparation magnezium orotate significant decrease of degree of desensitization of of erythrocytes has been noted.

Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Catecholamines; Connective Tissue Diseases; Erythrocyte Membrane; Female; Humans; Male; Orotic Acid; Receptors, Adrenergic, beta; Sympathetic Nervous System; Treatment Outcome

2011

Other Studies

1 other study(ies) available for magnesium-orotate and Connective-Tissue-Diseases

Article	Year
[Clinical value of the use of magnesium orotate in adolescents with syndrome of cardiac connective tissue dysplasia]. Kardiologiia, 2005, Volume: 45, Issue:3 According to results of clinical and instrumental investigation magnesium orotate (50 mg/day during first week and 25 mg/day thereafter) was found to be effective therapy of children with syndrome of cardiac connective tissue dysplasia (mainly with mitral valve prolapse and anomalous chordae tendineae). Topics: Adolescent; Blood Pressure; Child; Chordae Tendineae; Connective Tissue Diseases; Female; Follow-Up Studies; Heart Rate; Humans; Male; Mitral Valve Prolapse; Orotic Acid; Retrospective Studies; Syndrome; Treatment Outcome	2005

Article

Year

[Clinical value of the use of magnesium orotate in adolescents with syndrome of cardiac connective tissue dysplasia].

Kardiologiia, 2005, Volume: 45, Issue:3

According to results of clinical and instrumental investigation magnesium orotate (50 mg/day during first week and 25 mg/day thereafter) was found to be effective therapy of children with syndrome of cardiac connective tissue dysplasia (mainly with mitral valve prolapse and anomalous chordae tendineae).

Topics: Adolescent; Blood Pressure; Child; Chordae Tendineae; Connective Tissue Diseases; Female; Follow-Up Studies; Heart Rate; Humans; Male; Mitral Valve Prolapse; Orotic Acid; Retrospective Studies; Syndrome; Treatment Outcome

2005